|
시장보고서
상품코드
1812606
진단학 분야 바이오마커 시장 - 세계 전략적 인사이트 및 예측(-2031년)Biomarkers in Diagnostics: Global Strategic Insights and Forecasts to 2031 |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
"진단학 분야 바이오마커 시장 - 세계 전략적 인사이트 및 예측(-2031년)"에서는 세계 임상 진단용 바이오마커 시장을 종합적으로 분석하고 2022년부터 2031년까지의 예측을 게재하고 있습니다. 본 보고서는 감염, 암, 심혈관질환, 일반 임상화학분석, 신경질환, 자가면역질환, 당뇨병, 대사 이상, 불임, 임신, 신장질환, 유전질환, 갑상선질환 등 7가지 주요 제품 카테고리에서 질환의 발견, 치료법 선택, 질환 모니터링, 치료 효과 평가에 사용되는 진단약 및 검사에 대해 연구하고 있습니다.
미국, 유럽, 중국, 중국, 인도, 일본 예측과 함께 각 카테고리 및 주요 하위 그룹별 세계 및 지역별 판매 데이터를 제공합니다. 시장 가치는 모두 바이오마커 관련 시약, 검사 키트, 소모품에 대한 최종사용자의 지출을 반영한 것이며, 진단 장비의 가치는 포함되지 않았습니다. 이 데이터는 제조업체, 실험실 관계자, 업계 전문가에 대한 광범위한 1차 인터뷰와 정부 통계, 산업 협회, 기업 제출 서류, Kalorama 간행물 등의 2차 정보를 바탕으로 작성되었습니다.
인구 고령화, 표적 치료제 도입, 진단 검사 시장 확대, 질량분석, 차세대 시퀀싱, 바이오인포매틱스 등 기술 발전 등 주요 산업 촉진요인을 조사하고 있습니다. 맞춤의료와 정밀의료에서 바이오마커의 역할, 약리유전체학 동향, 자동화, 리베이트, 혁신 파이프라인 등도 다루고 있습니다. 심층적인 경쟁 분석은 주요 체외진단 의약품 기업 및 바이오마커 전문 기업을 프로파일링하고, 제품화 된 제품, 새로운 기술, 시장 포지셔닝에 초점을 맞추고 있습니다.
상세한 세분화, 시장 동향, 전략적 인사이트를 통해 "진단학 분야 바이오마커 시장 - 2031년까지 세계 전략적 인사이트 및 예측(종양 마커, 신장질환 마커, 유전질환 마커, 심장 마커, 신경학 마커, 자가면역질환, 감염질환, 기타 마커)"은 바이오마커 분야에서 경쟁하는 기업이나 이 고성장 시장에 진출하고자 하는 기업에게 필수적인 자료가 될 것입니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 환경과 분석
- 개요
- 인구통계 패턴
- 총인구
- 65세 이상 인구
- 세계의 헬스케어 동향
- 의료비
- 병원
- 의사
- 환자 활동
- 입원
- 외과수술
- 외래 진료
- 세계 경제 기후
- 바이오마커 기술
- 바이오마커 분석에서 AI와 머신러닝의 역할 상승
- 바이오마커 시장 분석
- 주요 시장 동향
- 바이오마커 제품 시장
- 지리적 시장
제4장 감염증 바이오마커
- 개요
- 감염증 바이오마커 기술
- 감염증 주요 바이오마커
- 호흡기질환
- COVID-19
- 폐렴
- 인플루엔자
- A군 연쇄구균 감염증
- 결핵
- 기타 호흡기 감염증
- 의료 관련 감염증(HAI)
- 클로스트리디오이데스 디피실(C. diff)
- 패혈증
- 황색포도구균
- 엔테로코커스
- 기타 의료 관련 감염증
- 간염
- HIV
- 성감염증(STD)
- 인유두종바이러스(HPV)
- 클라미디아/임질(CT/NG)
- 트리코모나스증
- 단순포진바이러스(HSV-1 및 HSV-2)
- 기타 성감염증
- 매독
- 귀두염
- 연성하감
- 전염성 연부종
- 골반내 염증성 질환(PID)
- 음슬
- 옴
- 질염
- 토치
- 기타 감염증
- 말라리아
- 라임병
- 파일로리균
- 뎅기열
- 기타 모든 질환 바이오마커
- 샤가스병
- 시크로스포라증
- 낭충증
- 에볼라
- 한타바이러스
- 백선
- 웨스트 나일 바이러스(WNV)
- 지카바이러스
- 기타 감염증 바이오마커 판매
- 시장 분석
- 바이오마커 제품 공급업체
제5장 암 바이오마커
- 개요
- 암의 중요한 바이오마커
- 최근 동향
- 약물 유전자 적합성 예측 바이오마커 검사
- 약물 진단 검사
- 정밀 암 치료
- 액체 생검에 기반한 비침습성 암 분자진단
- 순환종양세포(CTC) 검사
- 엑소좀 시퀀싱
- 차세대 시퀀싱 검사
- 시장 분석
- 바이오마커 제품 공급업체
제6장 심혈관 바이오마커
- 개요
- 심혈관질환 주요 바이오마커
- 최근 동향
- 고감도 트로포닌(hs-cTn)
- 나트륨 이뇨 펩타이드(BNP/NT-proBNP)
- 염증 바이오마커
- 대사 및 지질 관련 바이오마커
- 신흥 바이오마커와 멀티오믹스 접근법
- AI와 머신러닝의 통합
- 시장 분석
- 바이오마커 제품 공급업체
제7장 임상화학 바이오마커
- 개요
- 임상화학의 주요 바이오마커
- 전해질과 혈액가스
- 소변 검사
- 워크스테이션 면역측정 검사
- 갑상선 검사
- 생식 능력과 기타 바이오마커
- 최근 동향
- 시장 분석
- 바이오마커 제품 공급업체
제8장 신경학적 바이오마커
- 개요
- 신경질환 주요 바이오마커
- 최근 동향
- 알츠하이머병 혈액 검사의 혁명
- 외상성 뇌손상(TBI) 바이오마커의 진보
- 디지털 뉴로 바이오마커와 AI/ML의 통합
- 기타 신경질환 바이오마커
- 멀티오믹스와 액체 생검 접근법
- 시장 분석
- 바이오마커 제품 공급업체
제9장 자가면역 바이오마커
- 개요
- 자가면역질환 주요 바이오마커
- 최근 동향
- 기존 자가항체를 넘어 확장
- 질환 진행과 치료 반응을 예측하기 위한 바이오마커
- 시장 분석
- 바이오마커 제품 공급업체
제10장 기타 바이오마커
- 개요
- 기타 질환의 중요한 바이오마커
- 당뇨병과 대사 바이오마커
- 임신과 생식에 관한 바이오마커
- 신장질환
- 유전성 질환
- 낭포성섬유증
- 다운증후군
- 겸상 적혈구증
- 고셔병
- 가족성 고콜레스테롤혈증
- 근 디스트로피
- 혈우병
- 폰빌레브란트병
- 신경섬유종증
- 다낭성 신장질환
- 척수성 근위축증
- 클라인펠터증후군
- 카나반병
- 뇌성마비
- 안젤만증후군(AS)
- 기타 유전성 질환
- 갑상선 질병
- 기타 모든 바이오마커
- 골질환 바이오마커
- 소화관 바이오마커
- 호흡기 바이오마커
- 분변 칼프로텍틴
- 시장 분석
제11장 기업 개요
- Abbott Diagnostics
- Asuragen(Bio-Techne)
- Becton Dickinson, and Company
- Bio-Rad Laboratories
- Biocartis
- Biodesix
- bioMerieux
- Biotheranostics, Inc.(Hologic)
- Danaher Corporation
- DiaSorin Group
- Exact Sciences
- Exosome Diagnostics(Bio-Techne)
- Illumina
- Myriad Genetics
- QuidelOrtho
- Qiagen
- Roche Diagnostics
- Siemens Healthineers
- Sysmex Inostics
- Thermo Fisher Scientific
Kalorama Information's "Biomarkers in Diagnostics: Global Strategic Insights and Forecasts to 2031" provides a comprehensive analysis of the worldwide clinical diagnostic biomarker market, with forecasts from 2022 through 2031. The report examines diagnostic substances and tests used for disease detection, therapy selection, disease monitoring, and evaluation of treatment effectiveness across seven major product categories: infectious diseases, cancer, cardiovascular diseases, general clinical chemistry analytes, neurological conditions, autoimmune conditions, and other conditions such as diabetes, metabolic disorders, fertility, pregnancy, kidney disorders, inherited diseases, and thyroid conditions.
Global and regional sales data-along with projections for the U.S., Europe, China, India, and Japan-are provided for each category and major subgroup. All market values reflect end-user spending on biomarker-related reagents, test kits, and consumables, excluding the value of diagnostic instruments. Data are compiled from extensive primary interviews with manufacturers, laboratory professionals, and industry experts, as well as secondary sources including government statistics, trade associations, company filings, and Kalorama publications.
The report explores key industry drivers such as aging populations, targeted therapy adoption, diagnostic test market expansion, and advances in technologies including mass spectrometry, next-generation sequencing, and bioinformatics. Coverage includes the role of biomarkers in personalized and precision medicine, trends in pharmacogenomics, automation, reimbursement, and innovation pipelines. Detailed competitive analysis profiles leading IVD companies and specialized biomarker firms, highlighting commercialized products, emerging technologies, and market positioning.
With in-depth segmentation, market trends, and strategic insights, "Biomarkers in Diagnostics: Global Strategic Insights and Forecasts to 2031 (Tumor Markers, Kidney Disorder Markers, Inherited Disease Markers, Cardiac Markers, Neurological Markers, Autoimmune Disorders, Infectious Disease, and Other Markers)" serves as an essential resource for companies competing in the biomarker space or seeking to enter this high-growth market.
Table of Contents
Chapter 1: Introduction
- About Kalorama Information
- Report Coverage
- Methodology
- Sources of Information
Chapter 2: Executive Summary
- Table 2-1: Global Biomarker Sales, by Product Group & Region, 2022-2031 ($ million) (Product Groups: Autoimmune, Cancer, Cardiovascular, Clinical Chemistry, Infectious Diseases, Neurological, Other) & (Africa/Middle East, Asia/Pacific, Central & South America, Eastern & Western Europe, North America)
Chapter 3: Market Environment & Analysis
- Overview
- Demographic Patterns
- Total Population
- Population Aged 65 Years & Older
- World Healthcare Trends
- Health Expenditures
- Hospitals
- Physicians
- Patient Activity
- Hospital Admissions
- Surgical Procedures
- Outpatient Consultations
- Table 3-1: Global Demographic & Healthcare Indicators, 2022-2031 (World Population, Healthcare Expenditures, Healthcare Resources, and Healthcare Activity)
- Global Economic Climate
- Biomarker Technologies
- The Rising Role of AI and Machine Learning in Biomarker Analysis
- Biomarker Market Analysis
- Key Market Trends
- Biomarker Product Markets
- Table 3-2: Global Biomarker Sales, by Product Group, 2022-2031 ($ million) (Autoimmune, Cancer, Cardiovascular, Clinical Chemistry, Infectious Diseases, Neurological, Other)
- Figure 3-1: Global Biomarker Sales, by Product Group, 2022-2031 ($ million) (Product Groups: Autoimmune, Cancer, Cardiovascular, Clinical Chemistry, Infectious Diseases, Neurological, Other)
- Figure 3-2: Global Biomarker Share, by Product Group, 2025 vs. 2031 (%) (Autoimmune, Cancer, Cardiovascular, Clinical Chemistry, Infectious Diseases, Neurological, Other)
- Geographical Markets
- Table 3-3: Global Biomarker Sales, by Region, 2022-2031 ($ million) (Africa/Middle East, Asia/Pacific (China, Japan, Other), Central & South America, Eastern & Western Europe, North America (U.S., Canada, Mexico))
- Figure 3-3: Global Biomarker Sales, by Region, 2022-2031 ($ million) (Africa/Middle East, Asia/Pacific, Central & South America, Eastern & Western Europe, North America)
- Figure 3-4: Global Biomarker Share, by Region, 2025 vs. 2031 (%) (Africa/Middle East, Asia/Pacific, Central & South America, Eastern & Western Europe, North America)
Chapter 4: Infectious Disease Biomarkers
- Overview
- Infectious Disease Biomarker Technologies
- Key Biomarkers for Infectious Disease
- Respiratory Diseases
- Table 4-1: Global Respiratory Disease Biomarker Sales, by Condition, 2022-2031 ($ million) (Group A Strep, Influenza, Pneumonia, Tuberculosis, Other)
- Figure 4-1: Global Respiratory Disease Biomarker Sales, by Condition, 2022-2031 ($ million) (Group A Strep, Influenza, Pneumonia, Tuberculosis, Other)
- Figure 4-2: Global Respiratory Disease Biomarker Share, by Condition, 2025 (%)
- Table 4-2: Global Respiratory Disease Biomarker Sales, by Technology, 2022-2031 ($ million) (Laboratory Immunoassay, Molecular, POC)
- Figure 4-3: Global Respiratory Disease Biomarker Sales, by Technology, 2022-2031 ($ million) (Laboratory Immunoassay, Molecular, POC)
- Figure 4-4: Global Respiratory Disease Biomarker Share, by Technology, 2025 (%) (Laboratory Immunoassay, Molecular, POC)
- COVID-19
- Pneumonia
- Influenza
- Group A Streptococcus Infections
- Tuberculosis
- Other Respiratory Infections
- Healthcare-Associated Infections (HAIs)
- Clostridioides difficile (c. diff)
- Sepsis
- Staphylococcus aureus
- Enterococcus
- Other Healthcare-Associated Infections
- Table 4-3: Global Healthcare-Associated Infections (HAIs) Biomarker Sales, by Type, 2022-2031 ($ million) (C. diff, Enterococci, Sepsis, Staph, Other)
- Figure 4-5: Global Healthcare-Associated Infections (HAIs) Biomarker Sales, by Type, 2022-2031 ($ million) (C. diff, Enterococci, Sepsis, Staph, Other)
- Figure 4-6: Global Healthcare-Associated Infections (HAIs) Biomarker Share, by Type, 2025 (%) (C. diff, Enterococci, Sepsis, Staph, Other)
- Hepatitis
- Table 4-4: Global Hepatitis Biomarker Sales, by Type, 2022-2031 ($ million) (Hepatitis B, Hepatitis C, Other Types)
- Figure 4-7: Global Hepatitis Biomarker Sales, by Type, 2022-2031 ($ million) (Hepatitis B, Hepatitis C, Other Types)
- Figure 4-8: Global Hepatitis Biomarker Share, by Type, 2025 (%) (Hepatitis B, Hepatitis C, Other Types)
- HIV
- Table 4-5: Global HIV Biomarker Sales, by Technology, 2022-2031 ($ million) (Immunoassay, Molecular, Rapid POC)
- Figure 4-9: Global HIV Biomarker Sales, by Technology, 2022-2031 ($ million) (Immunoassay, Molecular, Rapid POC)
- Figure 4-10: Global HIV Biomarker Share, by Technology, 2025 (%) (Immunoassay, Molecular, Rapid POC)
- Sexually Transmitted Diseases (STDs)
- Human Papillomavirus (HPV)
- Chlamydia/Gonorrhea (CT/NG)
- Trichomoniasis
- Herpes Simplex Virus (HSV-1 & HSV-2)
- Other Sexually Transmitted Diseases
- Syphilis
- Balanitis
- Chancroid
- Molluscum Contagiosum
- Pelvic Inflammatory Disease (PID)
- Pubic Lice
- Scabies
- Vaginitis
- Table 4-6: Global STD Biomarker Sales, by Type, 2022-2031 ($ million) (CT/NG, HPV, HSV 1&2, Trichomoniasis, Other)
- Figure 4-11: Global STD Biomarker Sales, by Type, 2022-2031 ($ million) (CT/NG, HPV, HSV 1&2, Trichomoniasis, Other)
- Figure 4-12: Global STD Biomarker Share, by Type, 2025 (%) (CT/NG, HPV, HSV 1&2, Trichomoniasis, Other)
- TORCH
- Table 4-7: Global TORCH Biomarker Sales, 2022-2031 ($ million)
- Figure 4-13: Global TORCH Biomarker Sales, 2022-2031 ($ million)
- Other Infectious Diseases
- Malaria
- Lyme Disease
- H. pylori
- Dengue
- All Other Disease Biomarkers
- Chagas Disease
- Cyclosporiasis
- Cysticercosis
- Ebola
- Hantavirus
- Ringworm
- West Nile Virus (WNV)
- Zika Virus
- Sales of Other Infectious Disease Biomarkers
- Table 4-8: Global Other Infectious Disease Biomarker Sales, by Type, 2022-2031 ($ million) (Malaria, Lyme Disease, E. Coli, H. pylori, Dengue, All Other)
- Figure 4-14: Global Other Infectious Disease Biomarker Sales, by Type, 2022-2031 ($ million) (Malaria, Lyme Disease, E. Coli, H. pylori, Dengue, All Other)
- Figure 4-15: Global Other Infectious Disease Biomarker Share, by Type, 2025 (%) (Malaria, Lyme Disease, E. Coli, H. pylori, Dengue, All Other)
- Respiratory Diseases
- Market Analysis
- Table 4-9: Global Infectious Disease Biomarker Sales, by Major Product Group, 2022-2031 ($ million) (HAIs, Hepatitis, HIV, Respiratory, STDs, TORCH, Other)
- Figure 4-16: Global Infectious Disease Biomarker Sales, by Major Product Group, 2022-2031 ($ million) (HAIs, Hepatitis, HIV, Respiratory, STDs, TORCH, Other)
- Figure 4-17: Global Infectious Disease Biomarker Share, by Major Product Group, 2025 (%) (HAIs, Hepatitis, HIV, Respiratory, STDs, TORCH, Other)
- Table 4-10: Global Infectious Disease Biomarker Sales, by Technology, 2022-2031 ($ million) (Lab Immunoassay Tests, Molecular Tests, Rapid Immunoassay Tests)
- Figure 4-18: Global Infectious Disease Biomarker Sales, by Technology, 2022-2031 ($ million) (Lab Immunoassay Tests, Molecular Tests, Rapid Immunoassay Tests)
- Figure 4-19: Global Infectious Disease Biomarker Share, by Technology, 2025 (%) (Lab Immunoassay Tests, Molecular Tests, Rapid Immunoassay Tests)
- Biomarker Product Suppliers
Chapter 5: Cancer Biomarkers
- Overview
- Key Biomarkers for Cancer
- Table 5-1: Global Cancer Biomarker Sales, by Type, 2022-2031 ($ million) (Circulating Tumor Markers (CTMs), Tissue Tumor Markers (TTMs))
- Figure 5-1: Global Cancer Biomarker Sales, by Type, 2022-2031 ($ million) (Circulating Tumor Markers (CTMs), Tissue Tumor Markers (TTMs))
- Figure 5-2: Global Cancer Biomarker Share, by Type, 2025 (%) (Circulating Tumor Markers (CTMs), Tissue Tumor Markers (TTMs))
- Recent Developments
- Predictive Biomarker Tests for Drug-Gene Match
- Pharmacodiagnostic Tests
- Precision Cancer Therapy
- Liquid Biopsy-based Non-Invasive Cancer Molecular Diagnostics
- Circulating Tumor Cell (CTC) Tests
- Exosome Sequencing
- Next-Generation Sequencing Tests
- Market Analysis
- Table 5-2: Global Cancer Biomarker Sales, by Condition, 2022-2031 ($ million) (Bladder, Breast, Colorectal, Esophageal, Kidney, Leukemias, Liver, Lung, Melanoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Ovarian, Pancreatic, Prostate, Stomach, Thyroid, Uterine, All Other)
- Figure 5-3: Global Cancer Biomarker Sales, by Condition, 2025-2031 ($ million) (Bladder, Breast, Colorectal, Esophageal, Kidney, Leukemias, Liver, Lung, Melanoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Ovarian, Pancreatic, Prostate, Stomach, Thyroid, Uterine, All Other)
- Figure 5-4: Global Cancer Biomarker Share, by Condition, 2025 (%) (Bladder, Breast, Colorectal, Esophageal, Kidney, Leukemias, Liver, Lung, Melanoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Ovarian, Pancreatic, Prostate, Stomach, Thyroid, Uterine, All Other)
- Biomarker Product Suppliers
Chapter 6: Cardiovascular Biomarkers
- Overview
- Key Biomarkers for Cardiovascular Conditions
- Recent Developments
- High-Sensitivity Troponins (hs-cTn)
- Natriuretic Peptides (BNP/NT-proBNP)
- Inflammatory Biomarkers
- Metabolic and Lipid-Related Biomarkers
- Emerging Biomarkers and Multi-Omics Approaches
- Integration of AI and Machine Learning
- Market Analysis
- Table 6-1: Global Cardiovascular Biomarker Sales, by Product Group, 2022-2031 ($ million) (Atherosclerosis, CAD (Coronary Artery Disease), Cerebrovascular, CHF (Congestive Heart Failure), Cholesterol/Lipid, Coagulation, MI (Myocardial Infarction), Other)
- Figure 6-1: Global Cardiovascular Biomarker Sales, by Product Group, 2022-2031 ($ million) (Atherosclerosis, CAD (Coronary Artery Disease), Cerebrovascular, CHF (Congestive Heart Failure), Cholesterol/Lipid, Coagulation, MI (Myocardial Infarction), Other)
- Figure 6-2: Global Cardiovascular Biomarker Share, by Product Group, 2025 (%) (Atherosclerosis, CAD (Coronary Artery Disease), Cerebrovascular, CHF (Congestive Heart Failure), Cholesterol/Lipid, Coagulation, MI (Myocardial Infarction), Other)
- Biomarker Product Suppliers
Chapter 7: Clinical Chemistry Biomarkers
- Overview
- Key Biomarkers for Clinical Chemistry
- Electrolytes and Blood Gases
- Urinalysis
- Workstation Immunoassay Tests
- Thyroid Testing
- Fertility and Other Biomarkers
- Recent Developments
- Market Analysis
- Table 7-1: Global Clinical Chemistry Biomarker Sales, by Product Group, 2022-2031 ($ million) (Cardiac Biomarkers, Drugs of Abuse, Electrolytes, Enzymes, Glucose, HbA1c, Proteins, Therapeutic Drugs, Other)
- Figure 7-1: Global Clinical Chemistry Biomarker Sales, by Product Group, 2022-2031 ($ million) (Cardiac Biomarkers, Drugs of Abuse, Electrolytes, Enzymes, Glucose, HbA1c, Proteins, Therapeutic Drugs, Other)
- Figure 7-2: Global Clinical Chemistry Biomarker Share, by Product Group, 2025 (%) (Cardiac Biomarkers, Drugs of Abuse, Electrolytes, Enzymes, Glucose, HbA1c, Proteins, Therapeutic Drugs, Other)
- Biomarker Product Suppliers
Chapter 8: Neurological Biomarkers
- Overview
- Key Biomarkers for Neurological Conditions
- Recent Developments
- Revolution in Alzheimer's Disease Blood Tests
- Advances in Traumatic Brain Injury (TBI) Biomarkers
- Digital Neuro Biomarkers and AI/ML Integration
- Biomarkers for Other Neurological Disorders
- Multi-Omics and Liquid Biopsy Approaches
- Market Analysis
- Table 8-1: Global Neurological Biomarker Sales, by Product Group, 2022-2031 ($ million) (Alzheimer's Disease, Epilepsy, Multiple Sclerosis, Neuropathy Disorders, Parkinson's Disease, Other)
- Figure 8-1: Global Neurological Biomarker Sales, by Product Group, 2022-2031 ($ million) (Alzheimer's Disease, Epilepsy, Multiple Sclerosis, Neuropathy Disorders, Parkinson's Disease, Other)
- Figure 8-2: Global Neurological Biomarker Share, by Product Group, 2025 (%) (Alzheimer's Disease, Epilepsy, Multiple Sclerosis, Neuropathy Disorders, Parkinson's Disease, Other)
- Biomarker Product Suppliers
Chapter 9: Autoimmune Biomarkers
- Overview
- Key Biomarkers for Autoimmune Diseases
- Recent Developments
- Expanding Beyond Traditional Autoantibodies
- Biomarkers for Predicting Disease Progression and Treatment Response
- Market Analysis
- Table 9-1: Global Autoimmune Biomarker Sales, by Product Group, 2022-2031 ($ million) (Celiac Disease, Crohn's Disease, Hashimoto's Thyroiditis, Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Type 1 Diabetes, Ulcerative Colitis, Other)
- Figure 9-1: Global Autoimmune Biomarker Sales, by Product Group, 2022-2031 ($ million) (Celiac Disease, Crohn's Disease, Hashimoto's Thyroiditis, Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Type 1 Diabetes, Ulcerative Colitis, Other)
- Figure 9-2: Global Autoimmune Biomarker Share, by Product Group, 2025 (%) (Celiac Disease, Crohn's Disease, Hashimoto's Thyroiditis, Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Type 1 Diabetes, Ulcerative Colitis, Other)
- Biomarker Product Suppliers
Chapter 10: Other Biomarkers
- Overview
- Key Biomarkers for Other Conditions
- Diabetes & Metabolic Biomarkers
- Fertility & Pregnancy Biomarkers
- Kidney Disorders
- Inherited Diseases
- Cystic Fibrosis
- Down Syndrome
- Sickle Cell Disease
- Gaucher Disease
- Familial Hypercholesterolemia
- Muscular Dystrophy
- Hemophilia
- Von Willebrand Disease
- Neurofibromatosis
- Polycystic Kidney Disease
- Spinal Muscular Atrophy
- Klinefelter Syndrome
- Canavan Disease
- Cerebral Palsy
- Angelman Syndrome (AS)
- Other Inherited Diseases
- Thyroid Conditions
- All Other Biomarkers
- Bone Disease Biomarkers
- Gastrointestinal Biomarkers
- Respiratory Biomarkers
- Fecal Calprotectin
- Market Analysis
- Table 10-1: Other Global Biomarker Sales, by Product Group, 2022-2031 ($ million) (Diabetes & Metabolic, Fertility & Pregnancy, Inherited Diseases, Kidney Disorders, Thyroid Conditions, All Other)
- Figure 10-1: Other Global Biomarker Sales, by Product Group, 2022-2031 ($ million) (Diabetes & Metabolic, Fertility & Pregnancy, Inherited Diseases, Kidney Disorders, Thyroid Conditions, All Other)
- Figure 10-2: Other Global Biomarker Share, by Product Group, 2025 (%) (Diabetes & Metabolic, Fertility & Pregnancy, Inherited Diseases, Kidney Disorders, Thyroid Conditions, All Other)
Chapter 11: Company Profiles
- Table 11-1: IVD Biomarker-Related Sales of Selected Industry Leaders, 2024 ($ million)
- Abbott Diagnostics
- Company Overview
- Point-of-Care Tests
- Core Laboratory
- Molecular Assays
- Companion Diagnostics
- Liquid Biopsy
- Financial
- Asuragen (Bio-Techne)
- Company Overview
- Financial
- Becton Dickinson, and Company
- Company Overview
- Financial
- Bio-Rad Laboratories
- Company Overview
- Financial
- Biocartis
- Company Overview
- Financial
- Biodesix
- Company Overview
- Financial
- bioMerieux
- Company Overview
- Financial
- Biotheranostics, Inc. (Hologic)
- Company Overview
- Financial
- Danaher Corporation
- Company Overview
- Cepheid
- Radiometer
- Beckman Coulter
- Leica Biosystems
- Financial
- DiaSorin Group
- Company Overview
- Financial
- Exact Sciences
- Company Overview
- Financial
- Exosome Diagnostics (Bio-Techne)
- Company Overview
- Financial
- Illumina
- Company Overview
- Financial
- Myriad Genetics
- Company Overview
- Financial
- QuidelOrtho
- Company Overview
- Financial
- Qiagen
- Company Overview
- Precision Medicine / Companion Diagnostics
- Liquid Biopsy
- Financial
- Roche Diagnostics
- Company Overview
- Molecular Testing
- HPV and Cervical Cancer Screening
- Immunohistochemistry - IHC
- Companion Diagnostics
- Circulating Tumor Cells
- Financial
- Siemens Healthineers
- Company Overview
- Financial
- Sysmex Inostics
- Company Overview
- Financial
- Thermo Fisher Scientific
- Company Overview
- Financial
샘플 요청 목록